Standardized and rapid assays for viable viral pathogens are needed to inform human health risk assessments.
Herein, we describe two rapid assays of use for characterizing protein PIPn binding interactions.
Rapid assays in bacteriology and virology are designed to provide earlier results to physicians and affect patient care.
RT-PCR is effective for the initial diagnosis and has greater sensitivity than other available rapid assays.
Lateral flow immunoassay (LFIA) represents a well established and appropriate technology among rapid assays because of its low cost and user-friendliness.
Our objective was to develop rapid assays to simultaneously detect these four organisms through the presence of antigen or DNA using the Luminex LabMAP™ system.
Background: Demand for the rapid diagnosis of influenza infections has increased with the advent of the availability of neuraminidase antiviral therapy for influenza A and B. Several rapid assays that detect both influenza A and B are now available.
These novel rapid assays can be applied to the specific detection and identification of H. influenzae for use in epidemiological studies and could also enable improved monitoring of invasive disease caused by these bacteria.
The ability of the two rapid assays to detect HIV-1 antibody-positive samples from commercial HIV-1 seroconversion panels contained in the pools was equivalent to that of commercial enzyme immunoassays (EIAs) and Western blot (WB) to detect HIV-1 antibody in the non-pooled samples.
These very rapid assays are essential for measuring pre-steady-state kinetics, which are discussed below.
The presence of two positive rapid assays was defined as HIV seropositive, and two negative rapid assays was defined as HIV seronegative.
